Conroy, T. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379, 2395–2406 (2018).

Article  CAS  Google Scholar 

Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).

Article  Google Scholar 

Zarkavelis, G. et al. Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG). ESMO Open 4, e000525 (2019).

Kindler, H. L. et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617–3622 (2010).

Philip, P. A. et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J. Clin. Oncol. 28, 3605–3610 (2010).

Article  CAS  Google Scholar 

Infante, J. R. et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur. J. Cancer 50, 2072–2081 (2014).

Article  CAS  Google Scholar 

Bodoky, G. et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest. N. Drugs 30, 1216–1223 (2012).

Van Cutsem, E. et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22, 1430–1438 (2004).

Article  Google Scholar 

Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960–1966 (2007).

Article  CAS  Google Scholar 

Golan, T. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. 381, 317–327 (2019).

Article  CAS  Google Scholar 

Wheler, J. J. et al. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res. 76, 3690–3701 (2016).

Article  CAS  Google Scholar 

Tsimberidou, A. M. et al. Initiative for molecular profiling and advanced cancer therapy (IMPACT): an MD Anderson Precision Medicine Study. JCO Precis. Oncol. https://doi.org/10.1200/PO.17.00002 (2017).

Tsimberidou, A. M., Fountzilas, E., Nikanjam, M. & Kurzrock, R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat. Rev. 86, 102019 (2020).

Article  CAS  Google Scholar 

Tsimberidou, A. M. et al. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J. Hematol. Oncol. 12, 145 (2019).

Article  CAS  Google Scholar 

Massard, C. et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 7, 586–595 (2017).

Article  CAS  Google Scholar 

Sicklick, J. K. et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat. Med. 25, 744–750 (2019).

Article  CAS  Google Scholar 

Ardito, C. M. et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22, 304–317 (2012).

Article  CAS  Google Scholar 

Yap, Y. S. et al. The NF1 gene revisited—from bench to bedside. Oncotarget 5, 5873–5892 (2014).

Article  Google Scholar 

Parish, A. J. et al. GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer 124, 4080–4089 (2018).

Article  CAS  Google Scholar 

Principe, D. R. et al. TGFbeta engages MEK/ERK to differentially regulate benign and malignant pancreas cell function. Oncogene 36, 4336–4348 (2017).

Article  CAS  Google Scholar 

Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 13, 828–851 (2014).

Article  CAS  Google Scholar 

Kato, S. et al. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. Int. J. Cancer 146, 3450–3460 (2020).

Article  CAS  Google Scholar 

Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P. & Knudsen, E. S. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle 10, 2497–2503 (2011).

Article  CAS  Google Scholar 

Wheler, J. J. et al. TP53 alterations correlate with response to VEGF/VEGFR inhibitors: implications for targeted therapeutics. Mol. Cancer Ther. 15, 2475–2485 (2016).

Article  CAS  Google Scholar 

Li, A. M., Boichard, A. & Kurzrock, R. Mutated TP53 is a marker of increased VEGF expression: analysis of 7525 pan-cancer tissues. Cancer Biol. Ther. 21, 95–100 (2020).

Article  Google Scholar 

Adashek, J. J., Goloubev, A., Kato, S. & Kurzrock, R. Missing the target in cancer therapy. Nat. Cancer 2, 369–371 (2021).

Article  Google Scholar 

Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).

Article  CAS  Google Scholar 

Ang, C. et al. Clinical benefit from trametinib in a patient with appendiceal adenocarcinoma with a GNAS R201H mutation. Case Rep. Oncol. 10, 548–552 (2017).

Article  Google Scholar 

Wilson, C. H., McIntyre, R. E., Arends, M. J. & Adams, D. J. The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene 29, 4567–4575 (2010).

Article  CAS  Google Scholar 

Ideno, N. et al. GNAS(R201C) induces pancreatic cystic neoplasms in mice that express activated KRAS by inhibiting YAP1 signaling. Gastroenterology 155, 1593–1607.e1512 (2018).

Article  CAS  Google Scholar 

Hattori, S. et al. Antibody against neurofibromatosis type 1 gene product reacts with a triton-insoluble GTPase activating protein toward ras p21. Biochem. Biophys. Res. Commun. 177, 83–89 (1991).

Article  CAS  Google Scholar 

Patel, H. et al. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J. Hematol. Oncol. 12, 130 (2019).

Article  CAS  Google Scholar 

Hong, D. S. et al. CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). J. Clin. Oncol. 38, 3511–3511 (2020).

Article  Google Scholar 

Al Baghdadi, T. et al. Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study. JCO Precis. Oncol. 3, 1–8 (2019).

Google Scholar 

Dudley, B. et al. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy. Cancer 124, 1691–1700, https://doi.org/10.1002/cncr.31242 (2018).

Article  CAS  Google Scholar 

Jones, M. R. et al. NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma. Clin. Cancer Res. 25, 4674–4681 (2019).

Article  CAS  Google Scholar 

Laskin, J. J. et al. Afatinib as a novel potential treatment option for NRG1 fusion-positive tumors. J. Glob. Oncol. 5, 110–110 (2019).

Article  Google Scholar 

Pishvaian, M. J. et al. Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative. Clin. Cancer Res. 24, 5018–5027 (2018).

Article  CAS  Google Scholar 

Kato, S. et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat. Commun. 11, 4965 (2020).

Article  CAS  Google Scholar 

Heestand, G. M. & Kurzrock, R. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget 6, 4553–4561 (2015).

Article  Google Scholar 

Schwaederle, M. et al. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist 19, 631–636 (2014).

Article  Google Scholar 

Botta, G. P. et al. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. JCI Insight https://doi.org/10.1172/jci.insight.150453 (2021).

Kato, S. et al. Concomitant MEK and cyclin gene alterations: implications for response to targeted therapeutics. Clin. Cancer Res. 27, 2792–2797 (2021).

Article  CAS  Google Scholar 

Kato, S. et al. Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors. Eur. J. Cancer 149, 184–192 (2021).

Article  CAS  Google Scholar 

Persha, H. E. et al. Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response. J. Hematol. Oncol. 15, 119 (2022).

Article  Google Scholar 

Nikanjam, M., Liu, S., Yang, J. & Kurzrock, R. Dosing three-drug combinations that include targeted anti-cancer agents: analysis of 37,763 patients. Oncologist 22, 576–584 (2017).

Article  CAS  Google Scholar 

Weiss, G. J. et al. Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making. Onco Targets Ther. 8, 959–967 (2015).

Article  Google Scholar 

Beaubier, N. et al. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget 10, 2384–2396 (2019).

Article  Google Scholar 

Frampton, G. M. et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31, 1023–1031 (2013).

Article  CAS  Google Scholar 

Odegaard, J. I. et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clin. Cancer Res. 24, 3539–3549 (2018).

Article  CAS